<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01903200</url>
  </required_header>
  <id_info>
    <org_study_id>6949-CL-0002</org_study_id>
    <nct_id>NCT01903200</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder</brief_title>
  <official_title>Phase I Study of FK949E - Multiple Dose Study of Elderly Adult Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study was to evaluate the safety and plasma concentration changes of&#xD;
      quetiapine after multiple oral administration of FK949E (extended-release formulation of&#xD;
      quetiapine) in elderly patients with major depressive disorder (MDD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of unchanged quetiapine</measure>
    <time_frame>For 24 hours after dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (area under the curve) of unchanged quetiapine</measure>
    <time_frame>For 24 hours after dosing.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax of plasma concentration of unchanged quetiapine</measure>
    <time_frame>For 24 hours after dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of plasma concentration of unchanged quetiapine</measure>
    <time_frame>For 24 hours after dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events, clinical tab tests, vital signs, 12-lead ECGs and physical exam</measure>
    <time_frame>Up to 25 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Major Depressive Disorder Patients</condition>
  <arm_group>
    <arm_group_label>FK949E Fed Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FK949E is administered after breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FK949E Fasted Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FK949E is administered in the morning under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FK949E</intervention_name>
    <description>Oral</description>
    <arm_group_label>FK949E Fasted Group</arm_group_label>
    <arm_group_label>FK949E Fed Group</arm_group_label>
    <other_name>extended release formulation of quetiapine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of major depressive disorder according to the DSM-IV-TR (Text Revision of&#xD;
             the Diagnostic and Statistical Manual of Mental Disorders version-4) criteria for any&#xD;
             of the following:&#xD;
&#xD;
               -  In case of not receiving antidepressant treatment: Patients with a diagnosis&#xD;
                  within 6 months prior to provision of written informed consent&#xD;
&#xD;
               -  In case of receiving antidepressant treatment: Patients continuously receiving&#xD;
                  antidepressant treatment at the time of providing written informed consent&#xD;
&#xD;
          -  Female patients of childbearing potential with a negative serum pregnancy test result&#xD;
             and who were willing and able to use a reliable method of birth control during the&#xD;
             study&#xD;
&#xD;
          -  Patients who could understand and comply with the requirements of the study, as judged&#xD;
             by the investigator/sub-investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A current or past history of a DSM-IV-TR Axis I disorder other than major depressive&#xD;
             disorder within 6 months prior to the study&#xD;
&#xD;
          -  Diagnosis of a DSM-IV-TR Axis II disorder that was considered to have a major impact&#xD;
             on the patient's current psychiatric status&#xD;
&#xD;
          -  A history of substance or alcohol abuse or dependence excluding caffeine and nicotine&#xD;
&#xD;
          -  Patients who were unable to abstain from drugs that induce or inhibit the&#xD;
             drug-metabolizing enzyme CYP3A4 from 14 days prior to the start of study drug&#xD;
             administration and throughout the study period&#xD;
&#xD;
          -  Patients showing evidence or signs of renal or hepatic failure, serious heart disease,&#xD;
             cerebrovascular disease, viral hepatitis B or C, or acquired immunodeficiency syndrome&#xD;
             (AIDS) (carrier)&#xD;
&#xD;
          -  Patients with any diagnosis of a neurological condition, such as Parkinson's disease,&#xD;
             Huntington's disease, essential tremor, multiple sclerosis, prior brain injury, space&#xD;
             occupying lesion, etc.&#xD;
&#xD;
          -  A clinical finding that is unstable (e.g., hypertension, unstable angina) or that, in&#xD;
             the opinion of the investigator or sub-investigator, would be negatively affected by&#xD;
             the study medication or that would affect the study medication&#xD;
&#xD;
          -  A current diagnosis of cancer (except basal or squamous cell skin carcinoma), unless&#xD;
             it has been in remission for at least 5 years.&#xD;
&#xD;
          -  Conditions that could affect absorption and metabolism of study medication (e.g.,&#xD;
             malabsorption syndrome, liver disease).&#xD;
&#xD;
          -  A current or past diagnosis of transient ischemic attack (TIA)&#xD;
&#xD;
          -  A history of seizure disorder, except for febrile convulsions&#xD;
&#xD;
          -  Receipt of electroconvulsive therapy within 90 days prior to the start of study drug&#xD;
             administration&#xD;
&#xD;
          -  Use of a depot antipsychotic injection and inability to be off the drug for a period&#xD;
             of twice the dosing interval prior to the start of study drug administration and&#xD;
             throughout the study period&#xD;
&#xD;
          -  Patients who, in the investigator's opinion, would require psychotherapy (other than&#xD;
             supportive psychotherapy) during the study period, unless psychotherapy had been&#xD;
             ongoing for a minimum of 90 days&#xD;
&#xD;
        before study drug administration&#xD;
&#xD;
          -  A score of ≥ 3 on the HAM-D17 Item (suicide) or a suicide attempt within the past 6&#xD;
             months, and those judged to be at serious suicidal or homicidal risk in the opinion of&#xD;
             the investigator/sub-investigator&#xD;
&#xD;
          -  A current or past history of diabetes mellitus* or glycated hemoglobin (HbA1c) of ≥&#xD;
             6.5% at screening within 2 months before the start of study drug administration&#xD;
             (*refer to the guidelines for monitoring blood glucose levels in patients treated with&#xD;
             atypical antipsychotics)&#xD;
&#xD;
          -  A white blood cell count (WBC) of ≤ 3,000/mm3 at screening assessment&#xD;
&#xD;
          -  Elevation of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values&#xD;
             at screening assessment (grade 2 or higher according to the &quot;Criteria for&#xD;
             Classification of the Grade of Adverse Drug Reactions to Pharmaceutical Products&quot;&#xD;
             (Pharmaceutical Affairs Bureau Safety Division's Notification No. 80 issued on 29 June&#xD;
             1992))&#xD;
&#xD;
          -  A known history of hypersensitivity to quetiapine or to any other component in the&#xD;
             FK949E tablets at the time of providing written informed consent&#xD;
&#xD;
          -  Treatment with quetiapine for depressive symptoms or bipolar disorder (mania) at the&#xD;
             time of providing written informed consent&#xD;
&#xD;
          -  Participation in another clinical study or post-marketing study within 12 weeks prior&#xD;
             to the start of study drug administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=176</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>July 17, 2013</study_first_submitted>
  <study_first_submitted_qc>July 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2013</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antipsychotic</keyword>
  <keyword>FK949E</keyword>
  <keyword>Quetiapine</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

